SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present an overview of AnaptysBio at the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be available on Monday September 13, 2021, at 7:00 a.m. ET via: https://journey.ct.events/view/9ece1408-084b-41dd-9e6e-8977a5086047
News
AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported operating results for the second quarter ended June 30, 2021 and provided pipeline updates. Click here to view original post… […]
News
AnaptysBio Announces Second Quarter 2019 Financial Results and?Provides Pipeline Updates
SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today reported operating result… […]
News
AnaptysBio Reports Positive Topline Data from Interim Analysis of GALLOP Phase 2 Clinical Trial of ANB019 Monotherapy in Moderate-to-Severe Generalized Pustular Psoriasis
SAN DIEGO, Sept. 30, 2019 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced positive topli… […]
